PEG-MGF Research Peptide

PEG-MGF is a synthetic research compound made by attaching a polyethylene glycol chain to MGF, the 24-residue peptide from the end of the IGF-1Ec E domain. It is used in exploratory laboratory work on how PEGylation alters a short growth-factor peptide, and the conjugate itself has not yet been characterised in peer-reviewed studies.

PEGylation is the chemical attachment of polyethylene glycol, a chain of repeating ethylene oxide units, to a peptide or protein. The chain attracts a shell of water molecules, making the molecule behave as if it were much larger. It has been used in pharmaceutical research for decades, including on growth hormone and IGF-1.

Small peptides are generally cleared quickly by the kidneys and are exposed to protein-cutting enzymes. Adding PEG increases effective size and can shield the chain from those enzymes. MGF, at under 3,000 daltons, is the kind of molecule where those effects are expected to matter most, although they have not been measured for this conjugate.

The name does not specify the PEG. Listings reviewed in October 2026 described a two-unit PEG linker giving about 2,993 daltons, a 2 kDa chain giving about 5,000 daltons, and a product stated at about 3,825 daltons. Each is a different molecule, which is why the batch mass spectrometry result matters more for PEG-MGF than almost any other peptide.

Not one we could verify. The number 108174-48-7, which appears on some listings, is registered in PubChem to myxoma virus growth factor, a different protein that shares the abbreviation MGF. Another listing gives 1015036-03-4, but we found no public registry record for it. There is no PubChem compound record for PEG-MGF.

MGF is the unmodified 24-residue peptide, and it is the form used in nearly all published E-domain research on muscle, nerve and heart cells. PEG-MGF is the same peptide with a polyethylene glycol chain added, studied for questions about stability, clearance and delivery. Researchers often run both side by side, with MGF as the documented reference.

Both aim to make a peptide last longer, by different routes. PEGylation enlarges the molecule with an attached polymer chain. The Drug Affinity Complex in CJC-1295 with DAC is a small reactive group designed to bind albumin, borrowing that protein’s long life in circulation, and the same peptide without it is supplied as CJC-1295 no DAC + Ipamorelin.

Not as a characterised compound. The nearest published work linked the MGF peptide through PEG to chitosan nanoparticles and used it as a targeting tag for intranasal siRNA delivery in mice, rather than testing the conjugate’s own activity. Stability, half-life and receptor data for PEG-MGF have not been reported.

In a first-in-man study, Roche’s PEGylated IGF-1 had a half-life of 140 to 200 hours, far longer than the unmodified protein, and suppressed growth hormone secretion much less. In mice it allowed twice-weekly dosing. These results concern the 70-residue mature hormone carrying a large PEG chain, not the E-domain peptide.

Yes, and it often does. A 2018 IGF-1 study found that a 30 kDa PEG changed binding-protein affinity and cell responses, and that cutting the PEG off through a protease-sensitive linker restored the original properties. This is why PEGylated analogues are compared against their unmodified parent in the same assay.

No. In a 2015 mouse infarction study, the MGF E-domain peptide was released from microrods made of poly(ethylene glycol) dimethacrylate gel. The peptide was held inside the material, not chemically joined to PEG. PEGylation, as in PEG-MGF, attaches the polymer to the peptide itself, so the two approaches answer different questions.

PEG-MGF is not a controlled drug under the Misuse of Drugs Act 1971; the Class C polypeptide hormones listed are somatropin, somatrem, somatotropin and chorionic gonadotrophins. There is no licensed medicine containing PEG-MGF in the UK. It is sold as a research compound for laboratory use only, which is how Crown Peptides supplies it. This is general information, not legal advice.

PEG-MGF is coming soon to Crown Peptides in 2mg vials, available singly or in packs of 3, 5 or 10 with a saving on every vial. Orders ship from the UK, and every batch is independently tested, with its Certificate of Analysis published on this page once stock arrives.

It depends on the PEG. At about 3,000 daltons, 2mg is roughly 0.67 micromoles; at about 5,000 daltons it is roughly 0.4 micromoles, and a larger share of the weight is polymer rather than peptide. Use the mass on your batch’s Certificate of Analysis for exact molar calculations. The 5 and 10-vial packs keep a longer project on a single batch.

Keep the unreconstituted powder at -20°C ± 5°C, dry and away from light. PEG readily absorbs moisture from the air and its chains can slowly oxidise, so vials are best kept sealed and allowed to reach room temperature before opening to avoid condensation. Prepared solutions should follow conditions validated for your study design.